9月10日，亚盛医药盘中下跌5.09%，报32.44港元/股，成交额5313.37万港元。
亚盛医药所在的生物科技行业整体走弱，个股中，信达生物跌3.0%，康方生物跌1.0%，三生制药跌3.59%，百济神州跌0.48%，云顶新耀跌7.37%。
亚盛医药集团是一家主要从事血液系统恶性肿瘤疗法的发现、开发和商业化的投资控股公司，核心产品包括耐立克（奥雷巴替尼）及利沙托克拉等，主要用于治疗慢性髓性白血病、急性髓性白血病等多种血液系统恶性肿瘤。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.